Should I Buy NRSN? NRSN 2026 Analysis

Should You Buy Neurosense Therapeutics Ltd (NRSN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

1.040

1 Day change

4.00%

52 Week Range

2.600

Analysis Updated At

2026/02/13

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

NeuroSense Therapeutics Ltd (NRSN) is not a strong buy for a beginner investor with a long-term strategy at this time. While the company has made progress in securing intellectual property for its drug PrimeC, the financial performance is weak, and there are no significant trading signals or trends to suggest immediate upside potential. The technical indicators are neutral, and the stock lacks strong momentum or catalysts for a long-term investment.

Technical Analysis

The MACD is positive and expanding, suggesting slight bullish momentum. RSI is neutral at 61.688, indicating no overbought or oversold conditions. Moving averages are converging, showing no clear trend. Key support and resistance levels are Pivot: 0.951, R1: 1.035, S1: 0.868, R2: 1.087, S2: 0.816.

Positive Catalysts

NeuroSense has secured Australian Patent No. 2022370513 for its drug PrimeC, enhancing its global intellectual property protection. PrimeC is positioned to address the growing demand for ALS treatments, projected to increase by 24% by 2040.

Neutral/Negative Catalysts

There are no significant trading trends from hedge funds or insiders.

Financial Performance

In Q4 2024, revenue remained at 0 with no growth. Net income dropped by -100% YoY, and EPS declined by -74.32% YoY to -0.19. Gross margin remained at 0 with no improvement.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target changes are available for NRSN.

2 Analyst Rating

Wall Street analysts forecast NRSN stock price to rise

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 1.000

Low

7.5

Averages

8.25

High

Current: 1.000

Low

7.5

Averages

8.25

High

Noble Capital

Robert LeBoyer

initiated

AI Analysis

2025-10-14

Reason

Noble Capital

Robert LeBoyer

Price Target

AI Analysis

2025-10-14

initiated

Reason

Noble Capital analyst Robert LeBoyer initiated coverage of NeuroSense with an Outperform rating and $9 price target. Lead product PrimeC has completed two Phase 2 trials for Amyotrophic Lateral Sclerosis and has a Phase 3 trial planned for early 2026, notes the analyst, who adds that initial results from a Phase 2 study in Alzheimer's disease showed "promising data."

D. Boral Capital

Jason Kolbert

Buy

initiated

$14

2025-05-12

Reason

D. Boral Capital

Jason Kolbert

Price Target

$14

2025-05-12

initiated

Buy

Reason

D. Boral Capital analyst Jason Kolbert initiated coverage of NeuroSense with a Buy rating and $14 price target. NeuroSense is a clinical-stage biotechnology company advancing a novel combination therapy platform targeting neurodegenerative diseases, with its lead candidate, PrimeC, in development for amyotrophic lateral sclerosis, the analyst tells investors in a research note. The firm says its bullish stance is supported by a "differentiated mechanistic approach, encouraging early clinical signals, and a disciplined strategy toward regulatory and commercial milestones."

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NRSN

Unlock Now

NRSN Should I Buy

NRSN Should I Buy

Should You Buy Neurosense Therapeutics Ltd (NRSN) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch